Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.49 |
| ▸ | CLK3 | P49761 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | HSF1 | Q00613 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322991 | 0.92 | CLK2 (0.44) | HRH3CLK2CLK3DYRK1ASMN1; SMN2 | |
| SCHEMBL22663476 | 0.85 | MPO (0.42) | CLK2CLK3DYRK1ACYP4F2CYP4A11 | |
| SCHEMBL22198920 | 0.83 | CHRM4 (0.55) | HRH3SMN1; SMN2CHRM4 | |
| SCHEMBL17654136 | 0.82 | CHRM4 (0.41) | CHRM4 | |
| SCHEMBL31508102 | 0.82 | PARP10 (0.46) | — | |
| SCHEMBL10255943 | 0.82 | PARP10 (0.46) | — | |
| SCHEMBL4018813 | 0.82 | MCHR1 (0.43) | — | |
| SCHEMBL18937319 | 0.81 | HRH3 (0.51) | HRH3SMN1; SMN2CCNE1CDK2HSF1 | |
| SCHEMBL29350110 | 0.81 | HRH3 (0.51) | HRH3SMN1; SMN2CCNE1CDK2HSF1 | |
| SCHEMBL15780659 | 0.81 | CHRNA3 (0.54) | HRH3SMN1; SMN2CCNE1CDK2HSF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930838-B1 | N-(PYRIDINYL)ACETAMIDE DERIVATIVES AS P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-113727756-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS (CN) | 2023-10-17 | — | — | US | disclosed |
| CN-113956238-B | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3385262-B1 | 4-(3H-INDOL-5-YL)-N-(PYRIDIN-2-YL)PYRIMIDIN-2-AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2022-07-13 | — | — | EP | disclosed |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| CN-108290864-B | Protein kinase inhibitor and preparation method and medical application thereof | 甘李药业股份有限公司 | 2022-05-10 | — | — | CN | disclosed |
| US-20220135538-A1 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | CONSTELLATION PHARMACEUTICALS, INC. | 2022-05-05 | — | — | US | disclosed |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2021-12-02 | — | — | US | disclosed |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2021-12-02 | — | — | US | disclosed |
| CN-113727756-A | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2021-11-30 | — | — | CN | disclosed |
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | GAN & LEE PHARMACEUTICALS | 2021-08-17 | — | — | US | disclosed |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | GAN & LEE PHARMACEUTICALS (CN) | 2020-05-28 | — | — | US | disclosed |
| WO-2019035008-A1 | CDK4/6 INHIBITORS AND USE THEREOF | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2019-02-21 | — | — | WO | disclosed |
| EP-3385262-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | Gan & Lee Pharmaceuticals (CN) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017092635-A1 | PROTEIN KINASE INHIBITOR, PREPARATION METHOD AND MEDICAL USE THEREOF | 甘李药业股份有限公司 | 2017-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091476-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | HRH3 2629/4885CLK2 167/4885CLK3 151/4885 |
| US-20210371418-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | HRH3 2629/4885CLK2 167/4885CLK3 151/4885 |
| US-20200165239-A1 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF | ROR1, DMPK, CDK9 | HRH3 2629/4885CLK2 167/4885CLK3 151/4885 |
| US-11787801-B2 | Protein kinase inhibitors, preparation method and medical use thereof | ROR1, DMPK, CDK9 | HRH3 2629/4885CLK2 167/4885CLK3 151/4885 |
| US-11351170-B2 | Substituted pyrimidines as CDK4/6 inhibitors | CDK4, CDK6, CDK2 | HRH3 2356/4885CLK2 777/4885CLK3 1325/4885 |
| US-20220135538-A1 | P300/CBP HAT INHIBITORS AND METHODS FOR THEIR USE | EP300, KAT2A, HDAC1 | HRH3 446/4885CLK2 1770/4885CLK3 3393/4885 |
| US-20210128555-A1 | CDK4/6 INHIBITORS AND USE THEREOF | CDK4, CDK6, CDK1 | HRH3 2654/4885CLK2 495/4885CLK3 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.